The Unseen Hand: AI-Based Prescribing Decision Support Tools and the Evaluation of Drug Safety and Effectiveness

Harriet Dickinson (), Dana Y. Teltsch (), Jan Feifel (), Philip Hunt (), Enriqueta Vallejo-Yagüe (), Arti V. Virkud (), Katoo M. Muylle (), Taichi Ochi (), Macarius Donneyong (), Joseph Zabinski (), Victoria Y. Strauss () and Juan M. Hincapie-Castillo ()
Additional contact information
Harriet Dickinson: Gilead Sciences
Dana Y. Teltsch: Takeda
Jan Feifel: Merck Healthcare KGaA
Philip Hunt: ETH Zurich
Enriqueta Vallejo-Yagüe: AstraZeneca
Arti V. Virkud: University of North Carolina at Chapel Hill
Katoo M. Muylle: AstraZeneca BeLux
Taichi Ochi: University of Groningen
Macarius Donneyong: Ohio State University
Joseph Zabinski: OM1, Inc.
Victoria Y. Strauss: Boehringer Ingelheim
Juan M. Hincapie-Castillo: University of North Carolina at Chapel Hill

Drug Safety, 2024, vol. 47, issue 2, No 2, 117-123

Abstract: Abstract The use of artificial intelligence (AI)-based tools to guide prescribing decisions is full of promise and may enhance patient outcomes. These tools can perform actions such as choosing the ‘safest’ medication, choosing between competing medications, promoting de-prescribing or even predicting non-adherence. These tools can exist in a variety of formats; for example, they may be directly integrated into electronic medical records or they may exist in a stand-alone website accessible by a web browser. One potential impact of these tools is that they could manipulate our understanding of the benefit-risk of medicines in the real world. Currently, the benefit risk of approved medications is assessed according to carefully planned agreements covering spontaneous reporting systems and planned surveillance studies. But AI-based tools may limit or even block prescription to high-risk patients or prevent off-label use. The uptake and temporal availability of these tools may be uneven across healthcare systems and geographies, creating artefacts in data that are difficult to account for. It is also hard to estimate the ‘true impact’ that a tool had on a prescribing decision. International borders may also be highly porous to these tools, especially in cases where tools are available over the web. These tools already exist, and their use is likely to increase in the coming years. How they can be accounted for in benefit-risk decisions is yet to be seen.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-023-01376-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:47:y:2024:i:2:d:10.1007_s40264-023-01376-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-023-01376-3

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().